[Anti-HIV antibodies in patients treated with intravenous gammaglobulins]. 1987

T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005719 gamma-Globulins Serum globulins that migrate to the gamma region (most positively charged) upon ELECTROPHORESIS. At one time, gamma-globulins came to be used as a synonym for immunoglobulins since most immunoglobulins are gamma globulins and conversely most gamma globulins are immunoglobulins. But since some immunoglobulins exhibit an alpha or beta electrophoretic mobility, that usage is in decline. gamma-Globulin,gamma Globulin,gamma Globulins
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
January 1987, Lancet (London, England),
T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
July 1988, Annals of allergy,
T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
December 2014, Clinical and experimental immunology,
T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
June 1989, Presse medicale (Paris, France : 1983),
T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
September 1984, Presse medicale (Paris, France : 1983),
T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
November 1971, Voprosy okhrany materinstva i detstva,
T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
January 1996, Acta clinica Belgica,
T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
October 1994, Journal of neuroimmunology,
T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
January 1986, Annales francaises d'anesthesie et de reanimation,
T Ohno, and T Kanoh, and H Fujii, and T Okada, and N Funakoshi, and H Uchino
November 1991, American journal of hematology,
Copied contents to your clipboard!